Guardion Health Sciences, Inc. (GHSI)
NASDAQ: GHSI · IEX Real-Time Price · USD
8.28
+0.26 (3.24%)
At close: Apr 23, 2024, 4:00 PM
8.07
-0.21 (-2.54%)
After-hours: Apr 23, 2024, 4:00 PM EDT
Guardion Health Sciences Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for GHSI.
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for GHSI is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
---|---|---|---|---|
Strong Buy | 2 | 0 | 0 | 0 |
Buy | 0 | 0 | 0 | 0 |
Hold | 0 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 |
Total | 2 | 1 | 1 | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Feb 2, 2024 |
Ascendiant Capital | Ascendiant Capital | Strong Buy Initiates $38 | Strong Buy | Initiates | $38 | +352.90% | Jul 18, 2022 |
Maxim Group | Maxim Group | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +262.32% | Mar 8, 2022 |
Financial Forecast
Revenue This Year
13.72M
from 12.25M
Increased by 12.01%
Revenue Next Year
15.09M
from 13.72M
Increased by 10.00%
EPS This Year
-2.45
from 0.12
EPS Next Year
-1.04
from -2.45
Revenue Forecast
Revenue | 2024 | 2025 |
---|---|---|
High | 14.1M | 15.5M |
Avg | 13.7M | 15.1M |
Low | 13.2M | 14.5M |
Revenue Growth
Revenue Growth | 2024 | 2025 |
---|---|---|
High | 15.3% | 13.2% |
Avg | 12.0% | 10.0% |
Low | 7.6% | 5.7% |
EPS Forecast
EPS | 2024 | 2025 |
---|---|---|
High | -2.52 | -1.07 |
Avg | -2.45 | -1.04 |
Low | -2.35 | -1.00 |
EPS Growth
EPS Growth | 2024 | 2025 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.